Glycemic Control

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Top

Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124. DURATION (Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention with Exenatide Once-Weekly) is a series of multinational studies comparing once-weekly exenatide with other antihyperglycemic therapies for treatment of type 2 diabetes.

Efficacy & safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 wks in metformin-treated patients

Top

Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986-1993. In 2011, Pratley and colleagues reported 52-week data from a trial that explored treatment with the DPP-4 inhibitor, sitagliptin, and the GLP-1 receptor agonist, liraglutide, among subjects with type 2 diabetes and A1C 7.5%–10%.

Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: ACCORD BP Trial

Top

Exclusive! Expert commentary from Henry Ginsberg, MD, on this post-hoc analysis of ACCORD BP. Barzilay JI, Howard AG, Evans GW, et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care. 2012;35(7):1401-1405.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

Top

Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-1428. The authors of the current prospective study sought to examine the potential benefits of laparoscopic Roux-en-Y gastric bypass (LRYGB) among those with BMI 30-34.9 kg/m2 (class I obesity) and type 2 diabetes.

Effects of intensive glucose lowering in type 2 diabetes

Top

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study investigated the effects of intensive glucose-lowering therapy on CV event reduction among patients with type 2 diabetes and either risk factors for, or established, cardiovascular disease.

Waist-to-Height Ratio and Cardiovascular Risk Factors in Elderly Individuals at High Cardiovascular Risk

Top

Guasch-Ferré M, Bulló M, Martínez-González MÁ, Corella D, Estruch R, Covas MI, Arós F, Wärnberg J, Fiol M, Lapetra J, Muñoz MÁ, Serra-Majem L, Pintó X, Babio N, Díaz-López A, Salas-Salvadó J. Waist-to-Height Ratio and Cardiovascular Risk Factors in Elderly Individuals at High Cardiovascular Risk. PLoS One. 2012;7(8):e43275. Several anthropometric measurements have been associated with cardiovascular disease, type-2 diabetes mellitus and other cardiovascular risk conditions, such as hypertension or metabolic syndrome.

β-cell function preservation after 3.5 years of intensive diabetes therapy

Top

Harrison LB, Adams Huet B, Raskin P, Lingvay I. Beta cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412. To assess beta-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.

BLOOM-DM: Efficacy, Safety of Lorcaserin for Weight Loss Among Those with Type 2 Diabetes

Top

O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426-1436. The Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus (BLOOM-DM) study was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of lorcaserin (administered in conjunction with a lifestyle modification program) for weight loss among those with type 2 diabetes.

ARIC Study: Examining Hypertension Risk Based on A1C

Top

Bower JK, Appel JL, Matsushita K, et al. ARIC Study: Examining Hypertension Risk Based on A1C. Diabetes Care. 2012;35:1031-1037. Bower and colleagues examined the role of A1C as a predictor of hypertension among subjects with and without diabetes in the Atherosclerosis Risk in Communities (ARIC) study.

1 2 3 4 5 6 7 8 9 10  ... Next